Login to Your Account

Other News to Note

Wednesday, January 22, 2014

Amarantus Bioscience Holdings Inc., of San Francisco, completed the in-licensure of Eltoprazine from PGI Drug Discovery LLC, giving it worldwide rights except for Asian territories. The company plans to start a Phase IIb trial this year to treat Levadopa-induced dyskinesia associated with Parkinson’s disease. Eltoprazine is a 5HT1a/1b partial agonist small-molecule drug candidate.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription